AssetMark Inc’s Anavex Life Sciences AVXL Stock Holding History

AssetMark Inc’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-76	Closed	-$676	–	3377
2025 Q3	$676	Hold	76	–	–	﹤0.01%	2877
2025 Q2	$701	Buy	+76	New	+$649	﹤0.01%	2679

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

AssetMark Inc's AVXL Position: Q4 2025 in Review

AssetMark Inc sold out of Anavex Life Sciences (AVXL) in Q4 2025, closing a stake of 76 shares — an estimated $676 sold.

AssetMark Inc first reported a position in AVXL in Q2 2025 and held it in 2 quarters. The position peaked at $701 in Q2 2025. 184 funds tracked by Wall St. Rank hold AVXL as of Q4 2025.

AssetMark Inc reported no remaining Anavex Life Sciences position as of Q4 2025 after selling out during the quarter.
AssetMark Inc sold 76 Anavex Life Sciences shares in Q4 2025, an estimated $676.
AssetMark Inc first reported a position in Anavex Life Sciences in Q2 2025 and held it in 2 quarters.
AssetMark Inc's Anavex Life Sciences position peaked at $701 in Q2 2025.
184 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2025.

Based on AssetMark Inc's 13F filing for Q4 2025, filed 23 Jan 2026.